Arterial stiffness and kidney disease progression in the systolic blood pressure intervention trial

• Published in: Clinical nephrology Vol. 94; no. 1; pp. 26 - 35
• Main Authors: Nowak, Kristen L, Chonchol, Michel, Jovanovich, Anna, You, Zhiying, Ambrosius, Walter T, Cho, Monique E, Glasser, Stephen, Lash, James, Simmons, Debra L, Taylor, Addison, Weiner, Daniel, Rastogi, Anjay, Oparil, Suzanne, Supiano, Mark A
• Format: Journal Article
• Language: English
• Published: Germany Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 01.07.2020; Dustri-Verlag Dr. Karl Feistle
• Subjects: Aged; Blood pressure; Blood Pressure - physiology; Diabetes; Disease Progression; Humans; Kidney diseases; Middle Aged; Nephrology; Older people; Pulse Wave Analysis; Renal Insufficiency, Chronic - epidemiology; Renal Insufficiency, Chronic - physiopathology; Salt; Variables; Vascular Stiffness - physiology
• ISSN: 0301-0430
• DOI: 10.5414/CN109982

Arterial stiffness increases with both advancing age and chronic kidney disease (CKD) and may contribute to kidney function decline, but evidence is inconsistent. We hypothesized that greater baseline arterial stiffness (assessed as pulse pressure (PP) and carotid-femoral pulse-wave velocity CFPWV)) was independently associated with kidney disease progression over the follow-up period (3.8 years) in the Systolic Blood Pressure Intervention Trial (SPRINT). 8,815 SPRINT participants were included in the analysis of PP. 592 adults who participated in a SPRINT ancillary study that measured CFPWV were included in subgroup analyses. Cox proportional hazards analysis was used to examine the association between PP and time to kidney disease progression endpoints: (A) incident estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m in non-CKD participants at baseline; (B) 50% decline in eGFR, initiation of dialysis, or transplant in those with baseline CKD. Mixed model analyses examined the association of baseline PP/CFPWV with follow-up eGFR. Mean ± SD age was 68 ± 10 years, baseline PP was 62 ± 14 mmHg, and CFPWV was 10.8 ± 2.7 m/s. In the fully adjusted model, PP ≥ median was associated with an increased hazard of kidney disease progression endpoints (HR: 1.93 (1.43 - 2.61)). The association remained significant in individuals without (2.05 (1.47 - 2.87)) but not with baseline CKD (1.28 (0.55 - 2.65)). In fully adjusted models, higher baseline PP associated with eGFR decline (p < 0.0001 (all, CKD, non-CKD)), but baseline CFPWV did not. Among older adults at high risk for cardiovascular events, baseline PP was associated with kidney disease progression.